Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Genetically Engineered Cells (LMY-920) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of LMY-920 in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). LMY-920 is a type of chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T-cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T-cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T-cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Patients in this study also receive obinutuzumab prior to T-cell collection and cyclophosphamide and fludarabine before LMY-920 infusion. Obinutuzumab is a monoclonal antibody that may help control the disease and may decrease the number of CLL/SLL cells in the bloodstream, which may improve the quality of the CAR T-cells. Chemotherapy drugs such as cyclophosphamide and fludarabine are given before CAR T-cell infusions to prepare the body to receive the CAR T-cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell’s deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body’s immune response. Fludarabine injection is in a class of medications called purine analogs. It works by slowing or stopping the growth of cancer cells in the body. LMY-920 may be a safe treatment option for patients with relapsed or refractory CLL/SLL.